세계의 항우울제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 유통 채널별 예측(2025-2030년)

The Antidepressants Drugs Market was valued at USD 20.71 billion in 2023, expected to reach USD 22.44 billion in 2024, and is projected to grow at a CAGR of 9.85%, to USD 39.99 billion by 2030.

Antidepressant drugs, which encompass a broad range of medications such as SSRIs, SNRIs, MAOIs, and tricyclic antidepressants, are primarily designed to manage depression and associated disorders like anxiety, OCD, and PTSD. These medications function by altering chemical imbalances in the brain, which are thought to be responsible for mood changes and emotional states. The necessity for antidepressant drugs has been increasing, driven by the rising prevalence of mental health disorders, increased awareness, and reduced stigma surrounding mental health treatment. These drugs find application across various end-users, including hospitals, clinics, and household settings, making them widely accessible. Key growth factors include an expanding demographic of patients across the globe and advancements in drug formulations and delivery systems that improve efficacy and reduce side effects. Additionally, trends like telemedicine and online mental health services are expanding the reach and accessibility of antidepressants. However, the market faces limitations such as the stigma still attached to mental health medication in some cultures, potential side effects, and the existence of alternative therapies like psychotherapy and lifestyle interventions. Among potential opportunities, there is significant room for innovation in personalized medicine and the development of drugs with fewer side effects and quicker onset of action. Furthermore, opportunities exist in exploring biomarkers for better diagnostic and treatment tools and leveraging artificial intelligence for drug discovery processes. Nonetheless, the market faces challenges like stringent regulatory requirements, patent expirations, and the high cost of advanced medications. Research areas such as neuroplasticity and genetic markers may yield innovative treatments, while companies might focus on regional market expansion through strategic partnerships and collaborations. The nature of the market is highly competitive, characterized by the presence of several large pharmaceutical companies and growing generic drug manufacturers.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antidepressants Drugs Market

The Antidepressants Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidences of PTSD, OCD, and anxiety issues
  • Favorable government initiatives and campaigns for mental health problems
  • Rise in number of mental health institutions and professionals
• Market Restraints
  • Associated side effects and cost of antidepressants drugs
• Market Opportunities
  • Innovative solutions for the development of novel antidepressants drugs
  • Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
• Market Challenges
  • Social stigma surrounding mental health treatments

Porter's Five Forces: A Strategic Tool for Navigating the Antidepressants Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antidepressants Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antidepressants Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antidepressants Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antidepressants Drugs Market

A detailed market share analysis in the Antidepressants Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antidepressants Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antidepressants Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antidepressants Drugs Market

A strategic analysis of the Antidepressants Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidepressants Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Angelini Pharma S.p.a., Apotex Inc., AstraZeneca PLC, Biogen Inc., Bristol Myers Squibb Company, CAPLYTA by Intra-Cellular Therapies, Inc., Divi's Laboratories Limited, Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Eridanus Healthcare, H. Lundbeck A/S, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Mallinckrodt PLC, Merck & Co., Inc., Midas Pharma GmbH, Neurocon Inc., Organon & Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Somacare, SteriMax Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Antidepressants Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Monoamine Oxidase Inhibitors, Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Serotonin Antagonist, Serotonin-Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants.
• Based on Indication, market is studied across Anxiety Disorders, Attention Deficit Hyperactivity Disorder, and Major Depressive Disorder.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidences of PTSD, OCD, and anxiety issues
    • 5.1.1.2. Favorable government initiatives and campaigns for mental health problems
    • 5.1.1.3. Rise in number of mental health institutions and professionals
  • 5.1.2. Restraints
    • 5.1.2.1. Associated side effects and cost of antidepressants drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Innovative solutions for the development of novel antidepressants drugs
    • 5.1.3.2. Emerging regulatory approvals for new drugs and rising usage of SSRIs drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Social stigma surrounding mental health treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antidepressants Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Monoamine Oxidase Inhibitors
• 6.3. Reuptake Inhibitors
• 6.4. Selective Serotonin Reuptake Inhibitors
• 6.5. Serotonin Antagonist
• 6.6. Serotonin-Norepinephrine Reuptake Inhibitors
• 6.7. Tricyclic Antidepressants

7. Antidepressants Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Anxiety Disorders
• 7.3. Attention Deficit Hyperactivity Disorder
• 7.4. Major Depressive Disorder

8. Antidepressants Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Injectable
• 8.3. Oral

9. Antidepressants Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Antidepressants Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antidepressants Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antidepressants Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Alembic Pharma gets USFDA nod to market generic antidepressant drug
  • 13.3.2. Acquisition of CinCor Pharma complete
  • 13.3.3. Zydus gets USFDA nod to market generic medicine for treating depression
  • 13.3.4. RA Capital backs another startup hunting for a better antidepressant
  • 13.3.5. Autobahn raises funds for ABX-002 advancement to treat depression
  • 13.3.6. Axsome Therapeutics Announces FDA Approval of AUVELITY, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
  • 13.3.7. Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
  • 13.3.8. Osmind scores $40M investment to aid in mental health research and treatment
  • 13.3.9. Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck
  • 13.3.10. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
  • 13.3.11. Granules India gets USFDA approval for generic antidepressant drug
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. A. N. Pharmacia Laboratories Pvt. Ltd.
• 2. AbbVie Inc.
• 3. Alkermes PLC
• 4. Angelini Pharma S.p.a.
• 5. Apotex Inc.
• 6. AstraZeneca PLC
• 7. Biogen Inc.
• 8. Bristol Myers Squibb Company
• 9. CAPLYTA by Intra-Cellular Therapies, Inc.
• 10. Divi's Laboratories Limited
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Eisai Co., Ltd.
• 13. Eli Lilly and Company
• 14. Eridanus Healthcare
• 15. H. Lundbeck A/S
• 16. Jabs Biotech Pvt. Ltd.
• 17. Johnson & Johnson Services, Inc.
• 18. La Renon Healthcare Pvt. Ltd.
• 19. Lupin Ltd.
• 20. Mallinckrodt PLC
• 21. Merck & Co., Inc.
• 22. Midas Pharma GmbH
• 23. Neurocon Inc.
• 24. Organon & Co.
• 25. Otsuka Pharmaceutical Co., Ltd.
• 26. Pfizer Inc.
• 27. Sandoz International GmbH by Novartis AG
• 28. Sanofi S.A.
• 29. Somacare
• 30. SteriMax Inc.
• 31. Sun Pharmaceutical Industries Limited
• 32. Takeda Pharmaceutical Co. Ltd.
• 33. Teva Pharmaceutical Industries Ltd.
• 34. UCB S.A.
• 35. Wellona Pharma